{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:30Z","timestamp":1774935210852,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Secondary lymphedema is a common complication of cancer treatment for which no effective drug treatments yet exist. Level I clinical data suggests that doxycycline is effective for treating filariasis-induced lymphedema, in which it decreases tissue edema and skin abnormalities; however, this treatment has not been tested for cancer-related lymphedema. Over the past year, we used doxycycline in an off-label manner in patients with breast cancer-related secondary lymphedema. The purpose of this report was to retrospectively analyze the efficacy of this treatment.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients who presented to our lymphedema clinic between January 2021 and January 2022 were evaluated, and barring allergies or contraindications to doxycycline treatment, were counseled on the off-label use of this treatment. Patients who wished to proceed were treated with doxycycline (200\u00a0mg given orally once daily) for 6\u00a0weeks. After IRB approval of this study, lymphedema outcomes were retrospectively reviewed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Seventeen patients with a mean follow-up of 17.0 \u00b1 13.2\u00a0weeks were identified in our retrospective review. Although doxycycline treatment had no significant effect on relative limb volume change or L-Dex scores, we found a significant improvement in patient-reported quality of life. Analysis of patient responses to the Lymphedema Life Impact Scale showed a significant improvement in the total impairment score due to improvements in the physical and psychological well-being subscales (<jats:italic>p<\/jats:italic> = 0.03, <jats:italic>p<\/jats:italic> = 0.03, <jats:italic>p<\/jats:italic> = 0.04, respectively).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This small, retrospective study did not show significant improvements in limb volume or L-Dex scores in patients with breast cancer-related lymphedema treated with doxycycline. However, our patients reported improvements in quality-of-life measures using a validated lymphedema patient-reported outcome instrument. Our results suggest that doxycycline may be of use in patients with breast cancer-related lymphedema; however, larger and more rigorous studies are needed.<\/jats:p>","DOI":"10.3389\/fphar.2022.1028926","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:40:36Z","timestamp":1666248036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Doxycycline for the treatment of breast cancer-related lymphedema"],"prefix":"10.3389","volume":"13","author":[{"given":"Stav","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Coriddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghu P.","family":"Kataru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak J.","family":"Mehrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"111816","DOI":"10.1016\/j.yexcr.2020.111816","article-title":"Human adipose-derived stem cells support lymphangiogenesis in vitro by secretion of lymphangiogenic factors","volume":"388","author":"Ahmadzadeh","year":"2020","journal-title":"Exp. Cell. Res."},{"key":"B2","first-page":"73","article-title":"Lymphedema following breast cancer treatment, including sentinel lymph node biopsy","volume":"37","author":"Armer","year":"2004","journal-title":"Lymphology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/archsurg.137.11.1253","article-title":"Lymphedema and quality of life in survivors of early-stage breast cancer","volume":"137","author":"Beaulac","year":"2002","journal-title":"Arch. Surg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/2000656X.2012.714785","article-title":"Standardised measurements used to order compression garments can be used to calculate arm volumes to evaluate lymphoedema treatment","volume":"46","author":"Brorson","year":"2012","journal-title":"J. Plast. Surg. Hand Surg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/PRS.0000000000007783","article-title":"Surgical treatment of lymphedema: A systematic review and meta-analysis of controlled trials. Results of a consensus conference","volume":"147","author":"Chang","year":"2021","journal-title":"Plast. Reconstr. Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00063030-200620060-00007","article-title":"An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis","volume":"20","author":"Cheung","year":"2006","journal-title":"BioDrugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.108.793208","article-title":"Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo","volume":"119","author":"Conrad","year":"2009","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1002\/cncr.25458","article-title":"Lymphedema beyond breast cancer: A systematic review and meta-analysis of cancer-related secondary lymphedema","volume":"116","author":"Cormier","year":"2010","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/lrb.2018.0028","article-title":"Correlation of L-dex bioimpedance spectroscopy with limb volume and lymphatic function in lymphedema","volume":"17","author":"Coroneos","year":"2019","journal-title":"Lymphat. Res. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-060116-022900","article-title":"Lymphedema: Pathogenesis and novel therapies","volume":"69","author":"Dayan","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1371\/journal.ppat.0020092","article-title":"Doxycycline reduces plasma VEGF-C\/sVEGFR-3 and improves pathology in lymphatic filariasis","volume":"2","author":"Debrah","year":"2006","journal-title":"PLoS Pathog."},{"key":"B12","unstructured":"Prescribing information\n            Doxycycline hyclate\n          2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/bf03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences.","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"B14","doi-asserted-by":"publisher","first-page":"140853","DOI":"10.1172\/JCI140853","article-title":"Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis","volume":"131","author":"Furlong-Silva","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41467-018-04418-y","article-title":"CD4(+) T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema","volume":"9","author":"Garc\u00eda Nores","year":"2018","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.biomaterials.2016.05.040","article-title":"Aligned nanofibrillar collagen scaffolds - guiding lymphangiogenesis for treatment of acquired lymphedema","volume":"102","author":"Hadamitzky","year":"2016","journal-title":"Biomaterials"},{"key":"B17","doi-asserted-by":"publisher","first-page":"OT1-06-01","DOI":"10.1158\/1538-7445.sabcs19-ot1-06-01","article-title":"Abstract OT1-06-01: Lymfactin, an investigational adenoviral gene therapy expressing VEGF-C, is currently studied in a double-blind, randomized, placebo-controlled, multicenter, phase 2 clinical study in patients suffering from breast cancer associated secondary lymphedema (BCAL)","volume":"80","author":"Hartiala","year":"2020","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.bjps.2020.05.009","article-title":"Phase 1 Lymfactin(\u24c7) study: Short-term safety of combined adenoviral VEGF-C and lymph node transfer treatment for upper extremity lymphedema","volume":"73","author":"Hartiala","year":"2020","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"B19","first-page":"177","article-title":"Quality of life and lymphedema following breast cancer","volume":"40","author":"Heiney","year":"2007","journal-title":"Lymphology"},{"key":"B20","unstructured":"Herantis announces inconclusive results from phase II study with lymfactin in breast cancer related lymphedema \u00ae\n            Herantis Pharma Plc\n          2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/SLA.0b013e31826ed043","article-title":"Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema","volume":"257","author":"Honkonen","year":"2013","journal-title":"Ann. Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0168259","DOI":"10.1371\/journal.pone.0168259","article-title":"Lymph node transplantation decreases swelling and restores immune responses in a transgenic model of lymphedema","volume":"11","author":"Huang","year":"2016","journal-title":"PloS one"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1016\/j.biomaterials.2011.02.051","article-title":"Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel","volume":"32","author":"Hwang","year":"2011","journal-title":"Biomaterials"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/lrb.2009.0002","article-title":"Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: Immunohistochemical and molecular characterization","volume":"7","author":"Jin","year":"2009","journal-title":"Lymphat. Res. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1559827617742108","article-title":"Lifestyle modification group for lymphedema and obesity results in significant health outcomes","volume":"14","author":"Keith","year":"2020","journal-title":"Am. J. Lifestyle Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000343699","article-title":"Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis","volume":"50","author":"Kim","year":"2013","journal-title":"J. Vasc. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fpsyt.2019.00407","article-title":"Placebo effect in the treatment of depression and anxiety","volume":"10","author":"Kirsch","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/CIRCULATIONAHA.110.965384","article-title":"Growth factor therapy and autologous lymph node transfer in lymphedema","volume":"123","author":"L\u00e4hteenvuo","year":"2011","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1089\/104454902762053855","article-title":"Adenovirus and adeno-associated virus vectors","volume":"21","author":"Lai","year":"2002","journal-title":"DNA Cell. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fonc.2016.00192","article-title":"The impact of L-dex(\u00ae) measurements in assessing breast cancer-related lymphedema as part of routine clinical practice","volume":"6","author":"Laidley","year":"2016","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3390\/ijms21072546","article-title":"Histopathologic features of lymphedema: A molecular review","volume":"21","author":"Li","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.vph.2008.01.010","article-title":"Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymphedema","volume":"49","author":"Liu","year":"2008","journal-title":"Vasc. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cis486","article-title":"Doxycycline improves filarial lymphedema independent of active filarial infection: A randomized controlled trial","volume":"55","author":"Mand","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"154e","DOI":"10.1097\/PRS.0000000000000268","article-title":"Lymphedema and obesity: Is there a link?","volume":"134","author":"Mehrara","year":"2014","journal-title":"Plast. Reconstr. Surg."},{"key":"B36","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/biology10090934","article-title":"Pilot study of anti-Th2 immunotherapy for the treatment of breast cancer-related upper extremity lymphedema","volume":"10","author":"Mehrara","year":"2021","journal-title":"Biology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/PRS.0000000000008590","article-title":"Nanofibrillar collagen scaffold enhances edema reduction and formation of new lymphatic collectors after lymphedema surgery","volume":"148","author":"Nguyen","year":"2021","journal-title":"Plast. Reconstr. Surg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jso.26679","article-title":"Lymphatic regeneration after implantation of aligned nanofibrillar collagen scaffolds: Preliminary preclinical and clinical results","volume":"125","author":"Nguyen","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMcp1803290","article-title":"Lymphedema after breast cancer treatment","volume":"379","author":"Rockson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1196\/annals.1413.014","article-title":"Estimating the population burden of lymphedema","volume":"1131","author":"Rockson","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"123775","DOI":"10.1172\/jci.insight.123775","article-title":"Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema","volume":"3","author":"Rockson","year":"2018","journal-title":"JCI insight"},{"key":"B42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1084\/jem.20020587","article-title":"Lymphangiogenic gene therapy with minimal blood vascular side effects","volume":"196","author":"Saaristo","year":"2002","journal-title":"J. Exp. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/iid3.32","article-title":"VEGF-C improves regeneration and lymphatic reconnection of transplanted autologous lymph node fragments: An animal model for secondary lymphedema treatment","volume":"2","author":"Schindewolffs","year":"2014","journal-title":"Immun. Inflamm. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ar.22438","article-title":"Improved regeneration of autologous transplanted lymph node fragments by VEGF-C treatment","volume":"295","author":"Sommer","year":"2012","journal-title":"Anat. Rec. Hob. N. J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1096\/fj.02-0401fje","article-title":"Therapeutic lymphangiogenesis with human recombinant VEGF-C","volume":"16","author":"Szuba","year":"2002","journal-title":"FASEB J. official Publ. Fed. Am. Soc. Exp. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nm1689","article-title":"Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation","volume":"13","author":"Tammela","year":"2007","journal-title":"Nat. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B48","first-page":"128","article-title":"Validation of the lymphedema life impact scale (LLIS): A condition-specific measurement tool for persons with lymphedema","volume":"48","author":"Weiss","year":"2015","journal-title":"Lymphology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"E135","DOI":"10.3390\/cancers12010135","article-title":"Preoperative assessment of upper extremity secondary lymphedema","volume":"12","author":"Wiser","year":"2020","journal-title":"Cancers"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2217\/fon.11.121","article-title":"Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-\u03b21 inhibition","volume":"7","author":"Yan","year":"2011","journal-title":"Future Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1172\/JCI15830","article-title":"VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema","volume":"111","author":"Yoon","year":"2003","journal-title":"J. Clin. Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e49940","DOI":"10.1371\/journal.pone.0049940","article-title":"CD4(+) cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis","volume":"7","author":"Zampell","year":"2012","journal-title":"PloS one"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1028926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:40:44Z","timestamp":1666248044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1028926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":52,"alternative-id":["10.3389\/fphar.2022.1028926"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1028926","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1028926"}}